We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular for prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin Cancer Res (2017) 23(17):5112-5122. PMID: 28615267
Optimization and evaluation of a novel size based circulating tumor cell isolation system. PLoS ONE (2015) 10(9): e0138032. PMID: 26397728
DNA replication-dependent induction of gene proximity by androgen. Hum Mol Genet (2015) 15;24(4):963-71. PMID: 25281662
Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol (2014) 232(5):566-77. PMID: 24407904
I have set up a research team devoted to cancer genetic studies and biomarker development, in particular in male urological cancers. The mission of the research team is to reduce motility and morbidity of cancer patients by understanding cancer development and progression mechanisms and facilitating precision medicine through the development of efficient cancer detection, prognostic and treatment response prediction/monitoring biomarkers.
Our past work have been mainly focused on identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. Recently, our research work moved into circulation biomarker development, including CTCs, exosome and other cells, for cancer diagnosis, prognosis and prediction/monitoring of cancer progression and therapeutic response.
There are currently two main research areas of interest:
Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher FR, Olama AAA, Berndt SI et al. Nat Genet (2019) 51(2) 363
Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Vijayakrishnan J, Studd J, Broderick P et al. Nat Commun (2019) 10(2) 419
Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Matejcic M, Saunders EJ, Dadaev T et al. Nat Commun (2019) 10(2) 382
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Went M, Sud A, Försti A et al. Nat Commun (2019) 10(2) 213
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Sud A, Thomsen H, Law PJ et al. Nat Commun (2019) 10(2) 157
Author Correction: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. Mancuso N, Gayther S, Gusev A et al. Nat Commun (2019) 10(2) 171
Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Adams CD, Richmond R, Ferreira DLS et al. Cancer Epidemiol Biomarkers Prev (2019) 28(2) 208-216
AA9int: SNP interaction pattern search using non-hierarchical additive model set. Lin H-Y, Huang P-Y, Chen D-T et al. Bioinformatics (2018) 34(2) 4141-4150
Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia Vijayakrishnan J, Studd J, Broderick P et al. Nature Communications (2018) 9(1)
Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Matejcic M, Saunders EJ, Dadaev T et al. Nat Commun (2018) 9(2) 4616
Xueying Mao, Elzbieta Stankiewicz
Tanyu Guo, Caitlin Davis, Yeuzhou Zhang